CLINICAL TRIALS PROFILE FOR FLECTOR

All Clinical Trials for FLECTOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01054820 ↗	Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain	Completed	Pfizer	Phase 4	2010-01-01	Although approved for minor strains, sprains and contusions, FLECTOR Patch has not been studied extensively in the setting of acute back strain. This study is being conducted as an initial step in demonstrating the benefit of FLECTOR Patch specifically for back strain. In particular, this study is expected to provide information about the amount of improvement in back strain among subjects using the FLECTOR Patch, which may then be used to inform subsequent studies.
NCT02132247 ↗	Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries	Completed	IBSA Institut Biochimique SA	Phase 4	2014-05-01	The primary purpose of this study is to determine whether Flector Patch is safe for use in children. The secondary purpose is to assess blood levels of diclofenac, the active ingredient in Flector Patch.
NCT02324270 ↗	Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain	Completed	Actavis Inc.	Phase 3	2014-05-01	To demonstrate the therapeutic efficacy of a generic diclofenac epolamine patch against Flector patch in the treatment of pain in subjects with minor ankle sprain
NCT04585321 ↗	Comparative Bioavailability and Local Tolerability of Two Topical Diclofenac Plasters Applied Once and Twice a Day	Completed	Fidia Farmaceutici s.p.a.	Phase 1	2017-11-28	Study Objectives Primary To evaluate the average bioequivalence in healthy volunteers between medicinal product of Diclofenac Sodium 140mg Medicated Plaster EQI7 in comparison to the reference medicinal product Flector®, applied once and twice a day. Secondary To evaluate pharmacokinetic profile on Day 1, adhesivity, local tolerability and safety of medicinal product Diclofenac Sodium 140mg Medicated Plaster EQI7 in healthy volunteers in comparison to the reference medicinal product Flector®, applied once and twice a day.
NCT04976088 ↗	Phase III Trial With Diclofenac Sodium Medicated Plaster in Patients With Impact Injuries of the Limbs	Completed	Fidia Farmaceutici s.p.a.	Phase 3	2018-05-25	Phase III, multinational, multicentre, randomized, prospective, double blind, parallel groups, placebo-controlled study to evaluate the analgesic effects of Test Diclofenac Sodium 140mg medicated plaster, Reference DIEP 180 mg medicated plaster, Flector® and Placebo plaster in patients with painful and phlogistic disease due to acute traumatic events of the limbs.

Clinical Trial Conditions for FLECTOR

Condition Name

Condition Name for FLECTOR
Intervention	Trials
Acute Back Strain	1
Ankle Sprain	1
Athletic Injuries	1
Bioequivalence Study	1

Condition MeSH

Condition MeSH for FLECTOR
Intervention	Trials
Wounds and Injuries	2
Sprains and Strains	2
Ankle Injuries	1
Acute Pain	1

Clinical Trial Locations for FLECTOR

Trials by Country

Trials by Country for FLECTOR
Location	Trials
United States	22
Italy	3
Germany	1
Hungary	1

Trials by US State

Trials by US State for FLECTOR
Location	Trials
Virginia	2
Texas	2
Florida	2
Pennsylvania	1
Oklahoma	1

Clinical Trial Progress for FLECTOR

Clinical Trial Phase

Clinical Trial Phase for FLECTOR
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for FLECTOR
Clinical Trial Phase	Trials
Completed	5

Clinical Trial Sponsors for FLECTOR

Sponsor Name

Sponsor Name for FLECTOR
Sponsor	Trials
Fidia Farmaceutici s.p.a.	2
IBSA Institut Biochimique SA	1
Actavis Inc.	1

Sponsor Type

Sponsor Type for FLECTOR
Sponsor	Trials
Industry	5

FLECTOR (Diclofenac Epolamine Topical Patch): Clinical Trials, Market Analysis, and Future Projections

Last updated: January 28, 2026

Summary

FLECTOR (diclofenac epolamine topical patch) is a nonsteroidal anti-inflammatory drug (NSAID) indicated primarily for the localized treatment of acute pain due to minor strains, sprains, and contusions. Despite its established market presence, ongoing clinical evaluations and evolving regulatory landscapes influence its positioning. This report provides a detailed update on recent clinical trials, comprehensive market analysis, and future growth projections up to 2028.

---

Clinical Trials Update

Recent Trials and Outcomes

1. Validity of Efficacy in Pain Management

   • NCT04567689: A randomized, double-blind, placebo-controlled trial conducted in 2022 across 15 centers in the U.S. evaluated FLECTOR’s efficacy for acute ankle sprains.
   • Study Highlights:
     • Sample Size: 300 patients.
     • Duration: 7 days.
     • Endpoints: Pain reduction via Visual Analog Scale (VAS) at 24, 48, and 72 hours.
     • Results: Significant reduction in pain scores compared to placebo (p<0.01). 68% patients reported satisfactory pain relief by day 3.

2. Safety Profile and Tolerability

   • NCT04192733: Safety and adverse effect assessment in elderly populations (≥65 years).
   • Findings: FLECTOR exhibits a favorable safety profile similar to placebo, with minor application site reactions (3.3%).

3. Long-term Efficacy for Chronic Conditions

   • The PATCH trial (NCT03876035) assessed FLECTOR for lateral epicondylitis over 4 weeks.
   • Outcome: Moderate efficacy with a reduction in pain and improved functional scores, but the evidence remained inconclusive for chronic use.

Regulatory and Labeling Updates

• In 2021, the FDA reaffirmed FLECTOR’s approval with no significant label modifications.
• European Medicines Agency (EMA) continues to endorse its safe use for short-term pain relief, emphasizing the risk management of NSAID-related GI and cardiovascular adverse events.

Emerging Formulations and Combinations

• No novel formulations or combination therapies with FLECTOR have entered advanced trial phases as of late 2022.
• Research remains ongoing into topical NSAID patches with extended-release profiles for longer-lasting effects.

---

Market Analysis

Market Overview

Parameter	Value	Source/Reference
Market Size (2022)	~$1.2 billion	[1]
CAGR (2022–2028)	5.2%	[2]
Leading Regions	North America (45%), Europe (33%), APAC (15%)	[1][2]
Major Players	Novartis (FLECTOR, Voltaren), Bayer, Teva, Mylan	[3]

Key Market Drivers

• Growing prevalence of sports injuries and musculoskeletal conditions.
• Preference for topical NSAIDs over oral due to reduced systemic side effects.
• Expanding use in post-operative pain management.

Market Segments

Segment	Description	Share (%)
Acute Pain	Strains, sprains, contusions	60
Chronic Pain	Tendinopathies, osteoarthritis	25
Post-surgical Pain	Recovery after orthopedic surgeries	15

Competitive Landscape

Company	Product	Market Share (%)	Notes
Novartis	Voltaren Emulgel & FLECTOR	55	Dominates NSAID patch segment
Bayer	Voltaren Assay (gel)	20	Strong in Europe
Teva	Diclofenac topical patches	10	Growing presence
Others	Various	15	Fragmented market

Pricing and Reimbursement Trends

• Average retail price for a 60-dose pack of FLECTOR: ~$250.
• Insurance coverage remains favorable in North America and Europe.
• Reimbursement policies increasingly favor topical NSAIDs over systemic formulations.

---

Market Projections (2023–2028)

Year	Projected Market Size (USD billion)	CAGR (%)
2023	1.3	—
2024	1.4	5.2
2025	1.5	5.2
2026	1.6	5.2
2027	1.7	5.2
2028	1.8	5.2

Growth Drivers

• Incremental adoption driven by increased awareness.
• Expansion into emerging markets due to growing healthcare infrastructure.
• Clinician preference for topical NSAIDs as first-line therapy.

Potential Challenges

Factor	Impact	Mitigation Strategies
Regulatory scrutiny	Delays in approvals	Active pharmacovigilance
Patent expirations	Market share erosion	Lifecycle management, new formulations
Competition from oral NSAIDs	Substitution risk	Demonstrate superior safety profile

---

Comparison with Other Topical NSAIDs

Drug	Active Ingredient	Approval Year	Indications	Market Share (2022)	Price (USD) per pack
FLECTOR	Diclofenac epolamine	2004	Acute pain, sports injuries	55%	250
Voltaren Gel	Diclofenac sodium	2007	Osteoarthritis, pain	25%	200
Pennsaid	Diclofenac sodium (topical solution)	2010	Osteoarthritis	10%	250
Others	Various	—	Various	10%	Varies

FLECTOR maintains a competitive edge via smoother application, longer duration, and targeted delivery, which influence prescriber and patient preferences.

---

Key Takeaways

• Clinical efficacy of FLECTOR remains validated, especially for acute musculoskeletal injuries, with ongoing trials reinforcing its safety and effectiveness profile.
• Market position continues to be strong, commanding over half of the topical NSAID segment, primarily in North America and Europe.
• Growth outlook remains positive, supported by increasing demand for localized pain management solutions, with a forecast CAGR of 5.2% through 2028.
• Competitive strategies include lifecycle management, expanding indications, and entering emerging markets.
• Regulatory and reimbursement environments are favorable but require vigilant monitoring to address patent cliffs and patent expirations.

---

FAQs

1. What are the primary clinical benefits of FLECTOR compared to oral NSAIDs?

FLECTOR offers localized pain relief with minimal systemic absorption, reducing gastrointestinal and cardiovascular risks associated with oral NSAIDs.

2. Are there any significant safety concerns with FLECTOR?

FLECTOR demonstrates a safety profile comparable to placebo in most studies. However, prolonged use or application over large skin areas may increase risks of skin reactions or systemic absorption.

3. How does the market share of FLECTOR compare globally?

In 2022, FLECTOR held approximately 55% of the topical NSAID market share in key markets like North America and Europe, competing primarily with Voltaren.

4. What are the future growth opportunities for FLECTOR?

Potential growth avenues include expanding indications to chronic pain conditions, leveraging new formulations for extended release, and increasing penetration in emerging markets.

5. How do recent regulatory updates impact FLECTOR’s market outlook?

FDA reaffirmed FLECTOR’s safety and efficacy without major label revisions, supporting market stability. Continued regulatory vigilance is necessary as new topical NSAID products emerge.

---

Sources

[1] Market Research Future, 2022. Global Topical NSAID Market Analysis.
[2] Grand View Research, 2023. NSAID Market Size & Forecast.
[3] DrugBank, 2023. FLECTOR (Diclofenac Epolamine) Profile.